Alprazolam Market By Type (Xanax, Niravam, and Others), By Application (Anxiety, Panic Disorders, and Others), Industry Trends, Estimation & Forecast, 2023-2030

Market Definition

Alprazolam is used to treat anxiety and panic disorders. Alprazolam belongs to the benzodiazepines class of medications which act on the brain and nerves to produce a relaxing and calming effect. Alprazolam works by enhancing the effects of a specific natural chemical in the body gamma-aminobutyric acid (GABA).

The Alprazolam market was valued at 104.8 million US$ in 2022 and is projected to reach 152.5 million US$ by 2030, at a CAGR of 4.8% during the forecast period.

Alprazolam Market Revenue By, 2022-2030

Market Dynamics

The rising prevalence of anxiety and panic disorders is driving the demand for Alprazolam market. Anxiety disorder is the most common mental illness in the U.S. According to the World Health Organization (WHO), 284 million adults around the globe have anxiety in 2018, of which 179 million were female (63%), and 105 million were male (37%). According to the Anxiety and Depression Association of America (ADAA), anxiety disorders affect 40 million people age 18 and older in the United States, which is 18.1% of the population every year. Panic disorder affects 6 million adults, which is 2.7% of the United States population. Women are more likely to be affected as men. In Europe, 25% of the population suffers from depression or anxiety each year. Alprazolam is to treat anxiety disorders and panic disorder. Further, increasing geriatric population is a key driving factor of the market. Alprazolam is recommended for the geriatric population because these agents do not accumulate in the blood, rapidly cleared from circulation, and offer greater dosage flexibility. However, product recall and side effects of alprazolam might hamper the market growth. The product recall for alprazolam by regulatory bodies and voluntary recall is hampering the market growth. For instance, Mylan Pharmaceuticals has a voluntary recall of Alprazolam tablets. The recall is due to contamination from a foreign substance. The Alprazolam tablets are for the treatment of anxiety disorder and panic disorder. Moreover, increasing studies on alprazolam would provide lucrative opportunities for the market in coming years.

Market Segmentation

The global alprazolam market is mainly classified based on type and application. Type is further segmented into Xanax, Niravam, and Others. By application, the market is divided into Anxiety, Panic Disorders, and Others.

Xanax showed significant growth in 2019, owing to the increasing clinical studies on Xanax, the partnership between companies to develop and market its product globally, and commercialization of alprazolam. Xanax is used to treat anxiety and panic disorders. Xanax increases the neurotransmitter gamma-aminobutyric acid (GABA) in the brain that provides calmness and relaxed feeling. Xanax is a safe and effective medication.

Regional Analysis

Based on geography, the global alprazolam market is divided into North America, Europe, Asia-Pacific, South America, and Middle East & Africa. North America is further divided in the U.S., Canada, and Mexico, whereas Europe consists of the UK, Germany, France, Italy, and Rest of Europe. Asia-Pacific is segmented into India, China, Japan, South Korea, and Rest of Asia-Pacific. The South America region includes Brazil, Argentina, and the Rest of South America, while the Middle East & Africa is categorized into GCC Countries, Egypt, South Africa, and Rest of Middle East & Africa.

North America was dominating the global alprazolam market in 2019, due to the rising prevalence of anxiety and panic disorders, commercialization of regulatory approved alprazolam, rising number of awareness campaigns focused on ensuring timely diagnosis and treatment of anxiety and panic disorders, and increasing clinical studies on alprazolam. For instance, Engage Therapeutics, Inc., a clinical-stage biopharmaceutical company, has completed its Phase 2b StATES study of Staccato Alprazolam. Staccato alprazolam is being developed to rapidly terminate seizures in patients with epilepsy in two minutes or less and prevent recurrence of seizure within two hours.

Competitive landscape
Key players operating in the alprazolam industry include Zydus Cadila Pharmaceuticals Ltd., Pfizer Inc., Medtronic Plc, Amneal Pharmaceuticals Inc., Mylan NV, Terrace Pharmaceuticals Pvt. Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd., Cipla Limited, Novartis, and Abbott Healthcare Pvt. Ltd.

Commercialization of regulatory approved product, increasing R&D activities on Alprazolam, the collaboration between companies to develop and market alprazolam, and strategic acquisition of clinical-stage pharmaceutical company developing Alprazolam to expand the product line of the company and revenue are some of the strategy adopted by the companies. For instance, UCB has acquired Engage Therapeutics, Inc., a clinical-stage pharmaceutical company, that is developing Staccato Alprazolam for the rapid termination of an active epileptic seizure. The acquisition was made for US$ 125 million in cash and around US$ 145 million for potential milestone payments related to clinical development and the launch of Staccato Alprazolam.

Alprazolam Market Key Segments:

By Type
• Xanax
• Niravam
• Others

By Application
• Anxiety
• Panic Disorders
• Others

Key Global Alprazolam Industry Players
• Zydus Cadila Pharmaceuticals Ltd.
• Pfizer Inc.
• Medtronic Plc
• Amneal Pharmaceuticals Inc.
• Mylan NV
• Terrace Pharmaceuticals Pvt. Ltd.
• Lupin Limited
• Torrent Pharmaceuticals Ltd.
• Cipla Limited
• Novartis
• Abbott Healthcare Pvt. Ltd.

1. Market Introduction
1.1. Executive Summary
1.2. Market Definition
1.3. Market Scope

2. Research Methodology
2.1. Primary Research
2.2. Research Methodology
2.3. Assumptions & Exclusions
2.4. Secondary data sources

3. Alprazolam Market Overview
3.1. Report Segmentation & Scope
3.2. Key Market Trend
3.3. Drivers
3.3.1. Rising Prevalence of Anxiety and Panic Disorders
3.3.2. Increasing Geriatric Population
3.4. Restraints
3.4.1. Product Recall
3.4.2. Side effect of Alprazolam
3.5. Opportunity
3.5.1. Increasing studies on Alprazolam
3.6. Porter’s Five Forces Analysis
3.6.1. Porter’s Five Forces Analysis
3.7. Market Share Analysis

4. Type Overview
4.1. Introduction
4.1.1. Market Size & Forecast
4.2. Xanax
4.2.1. Market Size & Forecast
4.3. Niravam
4.3.1. Market Size & Forecast
4.4. Others
4.4.1. Market Size & Forecast

5. Application Overview
5.1. Introduction
5.1.1. Market Size & Forecast
5.2. Anxiety
5.2.1. Market Size & Forecast
5.3. Panic Disorders
5.3.1. Market Size & Forecast
5.4. Others
5.4.1. Market Size & Forecast

6. Alprazolam Market Regional Overview
6.1. Introduction
6.1.1. Market Size & Forecast
6.2. North America Alprazolam Market
6.2.1. North America Market Size & Forecast, By Country
6.2.2. North America Market Size & Forecast, By Type
6.2.3. North America Market Size & Forecast, By Application
6.2.4. U.S.
6.2.4.1. Market Size and Forecast
6.2.5. Canada
6.2.5.1. Market Size and Forecast
6.2.6. Mexico
6.2.6.1. Market Size and Forecast
6.3. Europe Alprazolam Market
6.3.1. Europe Market Size & Forecast, By Country
6.3.2. Europe Market Size & Forecast, By Type
6.3.3. Europe Market Size & Forecast, By Application
6.3.4. Germany
6.3.4.1. Market Size and Forecast
6.3.5. France
6.3.5.1. Market Size and Forecast
6.3.6. UK
6.3.6.1. Market Size and Forecast
6.3.7. Italy
6.3.7.1. Market Size and Forecast
6.3.8. Spain
6.3.8.1. Market Size and Forecast
6.3.9. Rest of Europe
6.3.9.1. Market Size and Forecast
6.4. Asia-Pacific Alprazolam Market
6.4.1. Asia-Pacific Market Size & Forecast, By Country
6.4.2. Asia-Pacific Market Size & Forecast, By Type
6.4.3. Asia-Pacific Market Size & Forecast, By Application
6.4.4. Japan
6.4.4.1. Market Size and Forecast
6.4.5. China
6.4.5.1. Market Size and Forecast
6.4.6. Australia
6.4.6.1. Market Size and Forecast
6.4.7. India
6.4.7.1. Market Size and Forecast
6.4.8. South Korea
6.4.8.1. Market Size and Forecast
6.4.9. Rest of Asia-Pacific
6.4.9.1. Market Size and Forecast
6.5. South America Alprazolam Market
6.5.1. South America Market Size & Forecast, By Country
6.5.2. South America Market Size & Forecast, By Type
6.5.3. South America Market Size & Forecast, By Application
6.5.4. Brazil
6.5.4.1. Market Size and Forecast
6.5.5. Argentina
6.5.5.1. Market Size and Forecast
6.5.6. Rest of South America
6.5.6.1. Market Size and Forecast
6.6. Middle East & Africa Alprazolam Market
6.6.1. Middle East & Africa Market Size & Forecast, By Country
6.6.2. Middle East & Africa Market Size & Forecast, By Type
6.6.3. Middle East & Africa Market Size & Forecast, By Application
6.6.4. GCC Countries
6.6.4.1. Market Size and Forecast
6.6.5. Egypt
6.6.5.1. Market Size and Forecast
6.6.6. South Africa
6.6.6.1. Market Size and Forecast
6.6.7. Rest of Middle East & Africa
6.6.7.1. Market Size and Forecast

7. Company Profile
7.1. Zydus Cadila Pharmaceuticals Ltd.
7.1.1. Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.1.2. Zydus Cadila Pharmaceuticals Ltd. Product Category, Application, and Specification
7.1.3. Zydus Cadila Pharmaceuticals Ltd. Financial Performance (2016-2018)
7.1.4. Main Business/Business Overview
7.2. Pfizer Inc.
7.3. Medtronic Plc
7.4. Amneal Pharmaceuticals Inc.
7.5. Mylan NV
7.6. Terrace Pharmaceuticals Pvt. Ltd.
7.7. Lupin Limited
7.8. Torrent Pharmaceuticals Ltd.
7.9. Cipla Limited
7.10. Novartis
7.11. Abbott Healthcare Pvt. Ltd.